Loading clinical trials...
Loading clinical trials...
A Phase II, Open (Partially Double-blind), Randomized, Controlled Dose-range Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Investigational Vaccination Regimens Versus MENINGITEC™ or MENCEVAX™ ACWY When Given as One Dose to Children Aged 12 to 14 Months and 3 to 5 Years Old
Conditions
Interventions
Conjugated meningococcal ACWY-TT (vaccine)
DTPa/Hib containing vaccine
+2 more
Locations
42
Austria
GSK Investigational Site
Güssing, Austria
GSK Investigational Site
Neufeld/Leitha, Austria
GSK Investigational Site
Salzburg, Austria
GSK Investigational Site
Villach, Austria
GSK Investigational Site
Wels, Austria
GSK Investigational Site
Bietigheim-Bissingen, Baden-Wurttemberg, Germany
Start Date
July 1, 2005
Primary Completion Date
February 1, 2008
Completion Date
February 1, 2008
Last Updated
October 7, 2016
NCT04886154
NCT01962207
NCT00508261
NCT01755689
NCT00974363
NCT00126945
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions